CA3062294A1 - Non-fused tricyclic compounds - Google Patents

Non-fused tricyclic compounds Download PDF

Info

Publication number
CA3062294A1
CA3062294A1 CA3062294A CA3062294A CA3062294A1 CA 3062294 A1 CA3062294 A1 CA 3062294A1 CA 3062294 A CA3062294 A CA 3062294A CA 3062294 A CA3062294 A CA 3062294A CA 3062294 A1 CA3062294 A1 CA 3062294A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
independently
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3062294A
Other languages
English (en)
French (fr)
Inventor
Andrei W. Konradi
Tracy Tzu-Ling Tang Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivace Therapeutics Inc
Original Assignee
Vivace Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivace Therapeutics Inc filed Critical Vivace Therapeutics Inc
Publication of CA3062294A1 publication Critical patent/CA3062294A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3062294A 2017-05-03 2018-05-02 Non-fused tricyclic compounds Abandoned CA3062294A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500937P 2017-05-03 2017-05-03
US62/500,937 2017-05-03
PCT/US2018/030721 WO2018204532A1 (en) 2017-05-03 2018-05-02 Non-fused tricyclic compounds

Publications (1)

Publication Number Publication Date
CA3062294A1 true CA3062294A1 (en) 2018-11-08

Family

ID=64016799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3062294A Abandoned CA3062294A1 (en) 2017-05-03 2018-05-02 Non-fused tricyclic compounds

Country Status (7)

Country Link
US (1) US11186554B2 (enExample)
EP (1) EP3618818A4 (enExample)
JP (1) JP2020518669A (enExample)
CN (1) CN111132673A (enExample)
AU (1) AU2018263921A1 (enExample)
CA (1) CA3062294A1 (enExample)
WO (1) WO2018204532A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132673A (zh) 2017-05-03 2020-05-08 维瓦斯治疗公司 非稠合三环化合物
CA3073543A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. Benzosulfonyl compounds
EP3720430A4 (en) 2017-12-06 2021-05-05 Vivace Therapeutics, Inc. BENZOCARBONYL COMPOUNDS
CA3100503A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds
CN109260200A (zh) * 2018-11-21 2019-01-25 南方科技大学 化合物dCTB在制备治疗癌性疼痛的药物中的应用
GB201819659D0 (en) 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse
MX2021011209A (es) * 2019-03-15 2022-01-19 Massachusetts Gen Hospital Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
EP3956033B1 (en) * 2019-04-16 2024-12-11 Vivace Therapeutics, Inc. Bicyclic compounds
MX2021014443A (es) * 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CN114174291A (zh) * 2019-07-29 2022-03-11 巴斯利尔药物国际股份公司 用于治疗癌症的1,2,4-噁二唑-5-酮衍生物
EP4146652A1 (en) * 2020-05-08 2023-03-15 Merck Patent GmbH Tricyclic heterocycles useful as tead binders
WO2021247634A1 (en) * 2020-06-03 2021-12-09 Dana-Farber Cancer Institute, Inc. Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
PE20240017A1 (es) 2020-09-30 2024-01-04 Univ Leuven Kath Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
JP2024505196A (ja) 2021-01-25 2024-02-05 イケナ オンコロジー， インコーポレイテッド 肺癌の処置において使用するためのｔｅａｄ阻害剤３－（イミダゾール－４－イル）－４－（アミノ）－ベンゼンスルホンアミドとｅｇｆｒ阻害剤及び／またはｍｅｋ阻害剤との組み合わせ
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CN115594680A (zh) * 2021-07-07 2023-01-13 武汉人福创新药物研发中心有限公司（Cn） 一种tead抑制剂
CN113461643A (zh) * 2021-07-20 2021-10-01 韶远科技（上海)有限公司 一种4-甲基苯磺酸[(3-氟氧杂环丁烷-3-基)甲基]酯的合成方法
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023057371A1 (en) 2021-10-04 2023-04-13 Basilea Pharmaceutica International Ag, Allschwil 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
WO2023060227A1 (en) 2021-10-07 2023-04-13 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4441056A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
IL312905A (en) 2021-12-01 2024-07-01 Boehringer Ingelheim Int Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
US20250313553A1 (en) 2021-12-01 2025-10-09 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US12030866B2 (en) 2021-12-23 2024-07-09 Springworks Therapeutics, Inc. 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD
WO2023116877A1 (zh) * 2021-12-24 2023-06-29 武汉人福创新药物研发中心有限公司 作为tead抑制剂的杂环化合物
JP2025503671A (ja) * 2022-01-14 2025-02-04 デウン ファーマシューティカル カンパニー リミテッド 癌細胞成長抑制効果を有する新規アミノベンゼン誘導体およびこれを有効成分として含む予防または治療用薬剤学的組成物
TW202340180A (zh) * 2022-01-30 2023-10-16 大陸商希格生科（深圳）有限公司 三環化合物及其應用
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023204822A1 (en) * 2022-04-22 2023-10-26 Vivace Therapeutics, Inc. Phenyl phosphine oxide compounds and methods of use thereof
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
AU2023262556A1 (en) 2022-04-28 2024-12-05 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
EP4592302A1 (en) * 2022-09-23 2025-07-30 Hangzhou Phecdamed Co., Ltd. Small molecule compound having phosphorylated aryl structure, and use thereof
UY40457A (es) 2022-09-29 2024-04-02 Insilico Medicine Ip Ltd Inhibidores de tead y métodos de uso de los mismos
WO2024092116A1 (en) 2022-10-26 2024-05-02 Ikena Oncology, Inc. Combination of tead inhibitors and egfr inhibitors and uses thereof
WO2024105610A1 (en) 2022-11-18 2024-05-23 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024173761A1 (en) 2023-02-17 2024-08-22 Ikena Oncology, Inc. Combinations comprising mek inhibitors for use in the treatment of cancer
EP4669319A1 (en) 2023-02-23 2025-12-31 Novartis AG TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT
CN120659608A (zh) 2023-02-23 2025-09-16 诺华股份有限公司 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
US20250019385A1 (en) 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025088571A1 (en) 2023-10-26 2025-05-01 Astrazeneca Ab Crystalline forms of tead inhibitor
WO2025141118A1 (en) 2023-12-27 2025-07-03 Institut National de la Santé et de la Recherche Médicale Arylalkyloxyindole compounds and derivatives and their use
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903106A (en) 1974-04-12 1975-09-02 Lilly Co Eli Pyrazole-3-carboxylic acids
US3895027A (en) 1974-04-12 1975-07-15 Lilly Co Eli Process for preparing pyrazole-3-carboxylic acids
DE2419970C3 (de) 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
JP2630432B2 (ja) 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
FI902771A7 (fi) 1989-06-09 1990-12-10 Warner Lambert Co Menetelmä anti-inflammatoristen 1,3,4-tiadiatsolien ja 1,3,4-oksadiatsolien valmistamiseksi
US4962119A (en) 1989-06-09 1990-10-09 Warner-Lambert Company Triazole derivatives of fenamates as antiinflammatory agents
US5066668A (en) 1989-06-09 1991-11-19 Warner-Lambert Co. Triazole derivatives of fenamates as antiinflammatory agents
US5114958A (en) 1991-05-09 1992-05-19 Warner-Lambert Company 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents
US5670526A (en) 1995-12-21 1997-09-23 Otsuka Pharmaceutical Co., Ltd. 1,3,4-oxadiazoles
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6211209B1 (en) 1997-08-08 2001-04-03 Warner-Lambert Company Method of inhibiting connective tissue degradation
DE69926914T2 (de) 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-heterozyklus-substituierte diarylaminen
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
CA2377100A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
CA2582247C (en) 2004-10-20 2014-02-11 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives
US8097650B2 (en) 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1
ZA200807263B (en) 2006-04-19 2009-11-25 Serono Lab Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors
WO2008057280A1 (en) * 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US8785440B2 (en) 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
KR101880966B1 (ko) * 2011-06-10 2018-07-23 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
EP2858635A1 (en) 2012-06-11 2015-04-15 The Regents of The University of California Inhibitors of hippo-yap signaling pathway
CN106573918B (zh) 2014-07-04 2020-06-16 默克专利股份有限公司 具有抗寄生虫活性的氮杂环庚烷基衍生物和包含它们的药物组合物
JP2018519245A (ja) 2015-04-03 2018-07-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
WO2017058716A1 (en) 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
DK3371165T3 (da) * 2015-11-04 2022-05-02 Merck Patent Gmbh Btk-inhibitor til anvendelse til behandling af kræft
CN111132673A (zh) 2017-05-03 2020-05-08 维瓦斯治疗公司 非稠合三环化合物
CA3073543A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. Benzosulfonyl compounds
EP3720430A4 (en) 2017-12-06 2021-05-05 Vivace Therapeutics, Inc. BENZOCARBONYL COMPOUNDS
CA3100503A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds

Also Published As

Publication number Publication date
US20200062721A1 (en) 2020-02-27
CN111132673A (zh) 2020-05-08
EP3618818A1 (en) 2020-03-11
US11186554B2 (en) 2021-11-30
JP2020518669A (ja) 2020-06-25
AU2018263921A1 (en) 2019-12-05
WO2018204532A1 (en) 2018-11-08
EP3618818A4 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
CA3062294A1 (en) Non-fused tricyclic compounds
EP3691623B1 (en) Benzosulfonyl compounds
US11661403B2 (en) Oxadiazole compounds
EP3956033B1 (en) Bicyclic compounds
US11866431B2 (en) Bicyclic compounds
CA3084648A1 (en) Benzocarbonyl compounds
WO2021102204A1 (en) Heteroaryl compounds
HK40068715B (en) Bicyclic compounds
HK40068715A (en) Bicyclic compounds
EA047446B1 (ru) Бициклические соединения
EA046394B1 (ru) Бициклические соединения

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231102